Navigation Links
Experimental Vaginal Gel Doesn't Ward Off HIV
Date:12/4/2008

South African women using Carraguard had no decrease in infections, trial found

THURSDAY, Dec. 4 (HealthDay News) -- A microbicidal vaginal gel called Carraguard doesn't protect women from HIV infection.

That's the conclusion of a study that included more than 6,200 sexually-active, HIV-negative women at three sites in South Africa.

The women were given either Carraguard or a placebo gel and told to use one applicator of gel and a condom each time they had vaginal sex. The women, who were followed for up to two years, visited a clinic every three months to have tests for HIV infection and pregnancy, pelvic examinations, risk reduction counseling, and treatment for curable sexually transmitted diseases and vaginal infections.

The rate of HIV infection among women using Carraguard was 3.3 per 100-woman years, compared with 3.8 per 100-woman years in the placebo group. Rates of self-reported gel use were similar in both groups (96.2 percent Carraguard, 95.9 percent placebo), but applicator testing indicated that actual gel use was much lower (41.1 percent Carraguard, 43.1 percent placebo). Self-reported condom use was 64.1 percent for both groups.

The findings were published in this week's issue of The Lancet.

"This study did not show Carraguard's efficacy in prevention of male-to-female transmission of HIV, although no safety concerns were recorded. Low levels of gel use could have compromised the potential to detect a significant protective effect. Although the results from this and other completed microbicide efficacy trials have been disappointing, the search for female-controlled HIV-prevention methods must continue," wrote researchers from the Population Council in New York City and their colleagues.

Carraguard, a carrageenan-based compound, was developed by the Population Council.

In an accompanying comment, Dr. Willard Cates and Dr. Paul Feldblum, of Family Health International in North Carolina, wrote that no single method of HIV prevention will be adequate.

"Rather a combination of partly effective prevention approaches will be bundled into packages targeted to specific populations. This bundling will involve behavioral, biomedical, and structural interventions, each designed to reinforce the effect of the other. The cumulative influence of combination prevention is our hope for thwarting the spread of HIV," they said.

More information

The U.S. Centers for Disease Control and Prevention has more about HIV infection risk factors and prevention.



-- Robert Preidt



SOURCE: The Lancet, news release, Dec. 5, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Experimental anti-cancer drug made from corn lillies kills brain tumor stem cells
2. Experimental Antidepressants Offer Faster Relief
3. Experimental drug shows promise in advanced kidney cancer
4. Experimental drug boosts survival in recurrent ovarian cancer
5. Experimental cancer pharmaceuticals under trial
6. Experimental Drug Fails Against Heart Failure
7. Experimental Drug Fights Prostate Cancer
8. Experimental technique at GUMC offers real-time analysis of breast cancer biopsies
9. Experimental Vaccine Halts Prostate Cancer in Mice
10. Experimental Biology 2008 Todays Research: Tomorrows Health, April 5-9
11. 52 minority scientists receive travel fellowships to Experimental Biology 2008
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Vaginal Gel Doesn't Ward Off HIV
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, ... Elite. The attorneys chosen by their peers for this recognition are considered among the ... Traurig Shareholders received special honors as members of this year’s Legal Elite Hall of ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway ... call for a minimum wage raise to $12 an hour by 2020 and then adjusting ... restore the lost value of the minimum wage, assure the wage floor does not erode ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Living, is proud to recognize Dr. Barry M. Weintraub as a prominent plastic ... most beautiful women in the world, and the most handsome men, look naturally ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone ... executive with extensive sequencing and genomics experience, as Vice President of North American Capital ... will be responsible for leading the sales team in the commercialization of the HTG ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... RIDGE, Ill. and INDIANAPOLIS ... of students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship ... The 2016 scholarship winners, announced today online at ... to let type 1 diabetes stand in the way ... Diabetes has supported the Foundation,s scholarship program since 2012, ...
(Date:6/23/2016)... N.J. , June 23, 2016  Guerbet announced ... Premier Inc.,s Supplier Horizon Award . ... year, Guerbet was recognized for its support of Premier ... creation through clinical excellence, and commitment to lower costs. ... to receive this recognition of our outstanding customer service ...
Breaking Medicine Technology: